Kite Pharma (KITE) Posts Q4 Loss of 85c/Share

Kite Pharma (NASDAQ: KITE) reported Q4 EPS of ($0.85), which may not compare with the analyst estimate of ($0.71). Revenue for the quarter came in at $4.89 million versus the consensus estimate of $4.54 million.

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Hertz cuts guidance, announces notes and stock offerings, shares sink
• All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade